T-cell depleted bone marrow transplantation for plasma cell myeloma. Report of a case and review of the results of BMT for myeloma.
A 37-year-old male patient with advanced refractory plasma cell myeloma underwent T-cell depleted bone marrow transplantation (BMT) after 7 years of active disease previously treated with combination chemotherapy and irradiation. After the BMT there was marked clinical improvement and the patient is currently in good clinical condition two years after the BMT was performed. However, residual myeloma cells are still seen in the marrow and stable levels of paraprotein are still present in the serum. No GVHD was encountered after BMT. The problems of BMT in myeloma are discussed with a review of the current pertinent literature.
Yehuda
A B
AB
Department of Internal Medicine A, Hadassah University Hospital, Jerusalem, Israel.
Or
R
R
Naparstek
E
E
Slavin
S
S
Polliack
A
A
D000328:Adult; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013601:T-Lymphocytes; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide; D008558:Melphalan